BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

WuXi NextCode’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic...
BioCentury | Jun 22, 2020
Finance

In a first for the British Business Bank, firm backs Epidarex’s new fund

Epidarex’s latest fund will give the trans-Atlantic firm the ability to retain larger stakes later into the life cycle of portfolio companies. The fund also marks the first life sciences cornerstone investment from the British...
BioCentury | Jun 20, 2020
Product Development

China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track

Weiji (危机), the Chinese term for crisis, combines the characters for “danger” and “opportunity,” an apt description of the challenge posed by COVID-19. While most of the world struggles with pandemic containment and ‘re-opening,’ China,...
BioCentury | Jun 19, 2020
Politics, Policy & Law

Juneteenth and our path forward: Letter from BioCentury’s Co-Founders

Editor’s Note: BioCentury’s co-founders, Chairman Karen Bernstein, Ph.D., and President & CEO David Flores, have written to the company’s employees about BioCentury’s response to racism and racial inequities in healthcare. It is published in its...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
BioCentury | Jun 6, 2020
Politics, Policy & Law

Beyond molecules and microbes: biopharma's responsibility to racial justice in and outside its own walls

The killing of George Floyd has made it clear that life sciences leaders cannot focus exclusively on molecules or microbes, that their missions include helping to heal social as well as physical pathologies. The uncomfortable...
BioCentury | May 21, 2020
Product Development

Industry is a white knight right now. Don’t throw it away

Biopharma is having a moment. All eyes are on drug, diagnostic and vaccine developers to get us out of this crisis and back to work. Now, companies -- individually and collectively -- must make good...
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

Led by veteran biotech entrepreneur Jean-Pierre Sommadossi, Atea believes an antiviral it had been developing to treat HCV has promise to treat COVID-19 in a population that extends beyond hospitalized patients. The company said Wednesday...
BioCentury | May 21, 2020
Politics, Policy & Law

Can the economy be saved by your right to choose COVID testing?

Combined virus and antibody testing is our best opportunity to identify those who can immediately but carefully return to work, and in doing so restart the economy while minimizing the epidemic’s resurgence. We argue that...
BioCentury | May 12, 2020
Product Development

Vaccine prospects for COVID-19: learnings from a 40-year biotech journey that’s still in progress

I have been in biotech research one way or another for over 40 years. This strange time of quarantine and self-isolation during the COVID-19 outbreak has given me time to reflect on how lessons from...
Items per page:
1 - 10 of 476